Here's the link to the actual Nasdaq Listing Requirements.

https://listingcenter.nasdaq.com/assets/initialguide.pdf

The key part being this....

Nasdaq Capital Market
Financial and Liquidity Requirements
Companies must meet all of the criteria under at least one of the three standards below.

BID PRICE..............$4

"* Currently traded companies qualifying solely under the Market Value Standard must meet the $50 million Market Value of Listed Securities and the applicable bid price requirement for 90 consecutive trading days before applying."

"Video Chart".......calling all shorts!

"Nasdaq supports reforms that reduce the burden of meritless class actions, recognizing that it
can be difficult to distinguish legitimate from frivolous cases. Litigation rules can raise the bar
for filing class actions by, for example, making it easier to impose sanctions for frivolous suits.
Steps to promote conclusive resolution of cases at an earlier stage would reduce the amount
and duration of leverage enjoyed by class action profiteers."

Wouldn't it be nice to see the Nasdaq step-up and do the right thing and thanks for a post that's not the PUMP, DUMP, SHORT rhetoric.

https://www.otcshortreport.com/company/CVSI

"A NASDAQ application also requires disclosure of certain inquiries, investigations, lawsuits, litigation, arbitrations, hearings and other legal and administrative proceedings involving the company, its officers or directors or ten percent (10%) or greater shareholders. Related to the company, the application requires disclosure of any proceedings within the ten years preceding the application date (i) that were initiated by any regulatory civil or criminal agency; (ii) which are material to the company and were asserted under state or federal securities, banking, insurance, tax or bankruptcy laws; or (iii) which are material to the company and allege fraud, deceit or misrepresentation. Backup and final disposition documents must be provided."

http://www.legalandcompliance.com/nasdaq-compliance/

Yes, the actual lawsuit is BS and any amount of time discussing it is a waste of time but the lawsuit is not my concern. Not being listed on the Nasdaq because of it is.

Not true!

"The complaint, filed in the United States District Court District of Nevada, captioned Smith v. CV Sciences, Inc. et al., Case No. 2:18-cv-01602 (D. Nev.), alleges that between June 19, 2017 and August 20, 2018, inclusive (the "Class Period"), Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose that its Patent #15/426,617: (1) received a non-final rejection from the USPTO on April 27, 2017; (2) a final rejection from the USPTO on December 14, 2017; and (3) as a result of the foregoing, Defendants' statements about CV Sciences' business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis."

Call it what you want but it is a real lawsuit to Nasdaq. One plaintiff or twenty doesn't matter and they always use the name Smith and having to guess, Smith isn't some individual as I stated.

I'm not going to pretend to know what Nasdaq rules are regarding listing a company being sued for security fraud but I do know one thing, there is no way to pump this.


Securities Class Action Filed Against CV Sciences, Inc. (CVSI) By Block & Leviton LLP; Investors Are Encouraged to Contact the Firm

PR Newswire PR Newswire•August 24, 2018

BOSTON, Aug. 24, 2018 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, announces that it has filed a securities fraud class action against CV Sciences, Inc. ("CV Sciences" or the "Company") (CVSI) and certain of its officers alleging violations of the federal securities laws and encourages shareholders to contact Block & Leviton ahead of the October 23, 2018 lead plaintiff deadline.

On August 20, 2018, Citron Research published a report on twitter alleging that CV Sciences' management misrepresented the status of one of its key patents. According to Citron Research, the Company failed to disclose a rejected patent that the Company "continue[d] to hype." As a result of the Citron report, CV Sciences stock plunged over 63% in volatile trading.

The complaint, filed in the United States District Court District of Nevada, captioned Smith v. CV Sciences, Inc. et al., Case No. 2:18-cv-01602 (D. Nev.), alleges that between June 19, 2017 and August 20, 2018, inclusive (the "Class Period"), Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose that its Patent #15/426,617: (1) received a non-final rejection from the USPTO on April 27, 2017; (2) a final rejection from the USPTO on December 14, 2017; and (3) as a result of the foregoing, Defendants' statements about CV Sciences' business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis.

If you purchased CVSI shares between June 19, 2017 and August 20, 2018 and wish to serve as a lead plaintiff, you must move the Court no later than October 23, 2018.

If you wish to become involved in the litigation or have questions about your legal rights, you are encouraged to contact Attorney John DeFelice at (888) 868-2385, by email at john@blockesq.com or by visiting http://shareholder.law/cvsi.

Confidentiality to whistleblowers or others with information relevant to this investigation is assured.

Block & Leviton LLP was recently ranked 4th among securities litigation firms by ISS for recoveries in 2017. The firm represents many of the nation's largest institutional investors and numerous individual investors in securities litigation throughout the country. Indeed, its lawyers have recovered billions of dollars for its clients.

The court in which this case is pending is located at 333 S Las Vegas Blvd, Las Vegas, NV 89101.

This notice may constitute attorney advertising.

CONTACT:

BLOCK & LEVITON LLP
John DeFelice
(617) 398-5600 phone
155 Federal Street, Suite 400
Boston, MA 02110
john@blockesq.com

Even the "Video Chart Guy" is working overtime on this one.

Be aware! He MAY be part of the problem.

IMO

Garbage yes but a real lawsuit none the less and the very real question is how will this (can this) impact Nasdaq ruling decision? The timing of this whole thing is a little too perfect and really stinks. CVSI has been targeted by some entity and Citron and these scumbag lawyers are just part of what's going on. If you've been around stocks long enough you have seen this tactic before. What's going on isn't about shorting stocks, this is about trying to bury this company. I received a reply from the SEC for my complaint against Citron (Left). This legal manuver to legitimize what Citron did will tie up CVSI in court battles for years to come and yes it's all BS but CVSI will now have to respond to this complaint. This is not going away anytime soon and these type of actions take years and $$$'s to settle and they have nothing to do with winning or losing, right or wrong. A company with pending legal action can be affected in many ways. CVSI will or should make some public statement about this. IMO

STOCK MARKET...ORGANIZED CRIME AT IT'S BEST!

That's all that happened here yesterday. Better get used to it because it's not going to change.

Note:

When the Video Chart Guy shows up it's a BIG RED FLAG.

He needs to rename himself "CALLING ALL SHORTS".

IMO

This company is a hoax!

That was the point of my comment.

And why did we hire another sales guy?

But hey, who cares if it's a hoax!

I'm sure there are volumes on this damn company that will never come to light. Avid was just a breadcrumb left for shareholders to prevent anyone from being able to pursue legal actions against the company and it's former CEO and board. Even Ronin has faded into the woodwork although I don't think they are done with us just yet and I don't mean that in a good way.

No doubt in my mind that Team Ronin helped bring about last RS. As to who set them to that task I have some ideas that tie to UTSW or some $$$ group tied to that. It was the easiest way to oust King & The Three Amigos who refused to stop milking the cow.

"The office must be shit"

That sounds about right! lol

".SO, I am concluding that CDMO better fill its under capacity problems, or else...."

Almost 9 months into 2018 and they've manage to sign a contract to produce a drug for a disease that effects 2 people world-wide.

Did that new woman vp sales person "hit the ground running" or what?

How pathetic is this stock?

Did Ronin forget to plug in the CDMO stock machine?

"It'll will impact our CDMO stock just as muck as this news."

I don't know, will it......................?

DGAP-News: MOLOGEN and ONCOLOGIE: Global assignment and co-development agreement relating to MOLOGEN's lead compound lefitolimod
PRESS RELEASE EQS
Aug. 16, 2018, 02:06 AM


MOLOGEN and ONCOLOGIE: Global assignment and co-development agreement relating to MOLOGEN's lead compound lefitolimod

The issuer is solely responsible for the content of this announcement.
PRESS RELEASE N 18/2018 of 16 August 2018

MOLOGEN and ONCOLOGIE: Global assignment and co-development agreement relating to MOLOGEN's lead compound lefitolimod

Term sheet: Global assignment and co-development agreement for lead compound lefitolimod

Substantial potential payments in milestones and in addition royalties - near-term consideration of EUR23 million

Pivotal IMPALA study with lefitolimod would be almost entirely funded

Berlin, 16 August 2018 - The biopharmaceutical company MOLOGEN AG yesterday signed, with the consent of the Supervisory Board, a term sheet outlining the framework for a global assignment of all intellectual property and other rights in MOLOGEN's lead compound lefitolimod to ONCOLOGIE and an expansion of the existing global co-development agreement between MOLOGEN and ONCOLOGIE. The potential total deal value would be over EUR1 billion plus low double digit royalties on net sales, representing an attractive upside for MOLOGEN. MOLOGEN would receive a near-term consideration of EUR23 million. This transaction would secure the major part of the funding for the pivotal IMPALA study until read-out, projected for 2020.
Dr Ignacio Faus, Chief Executive Officer (CEO) of MOLOGEN: "We are delighted to intensify our ongoing collaboration with ONCOLOGIE, which would not only cover to a large extent the funding of our pivotal IMPALA trial but would also allow for a timely conduct of lefitolimod combination studies to fully exploit its potential in immuno-oncology. This reflects our common belief that lefitolimod has the clear potential to become a paradigm-changing compound in this area. Long term revenues from this deal could reach more than EUR1 billion."
"Increasing our investment in lefitolimod furthers ONCOLOGIE's mission to acquire and develop innovative oncology drugs globally. We have great confidence in the value this agreement with MOLOGEN can bring to our growing pipeline, and the positive impact our continued collaboration can have on the lives of cancer patients around the world", said Dr Laura Benjamin, Chief Executive Officer of ONCOLOGIE.
Walter Miller, CFO of MOLOGEN: "Notably ONCOLOGIE, which is backed by strong international investors and a team of seasoned scientific and development experts, starts to emerge as a strong player in the immuno-oncology area. ONCOLOGIE's global strategy, that leverages the strengths of both the U.S. and the China regulatory and clinical opportunities, will enhance the global value of lefitolimod whose current pivotal trial is a European study."Global rights and co-development agreement for lefitolimod: Major part of funding of pivotal IMPALA study can be secured
The term sheet envisages that all rights to MOLOGEN's immunotherapeutic agent lefitolimod, including intellectual property (IP) and know-how, will be transferred to ONCOLOGIE. In return, MOLOGEN would receive short-term as well as development and sales milestone payments. ONCOLOGIE would be solely responsible for all development, manufacturing and commercialization activities relating to lefitolimod globally and bear the corresponding expenses. Under the co-development agreement, MOLOGEN would carry out certain manufacturing activities to supply the clinical medication. ONCOLOGIE would also obtain a Right of First Refusal to license the optioned products, EnanDIM(R) and MGN1601 - but excluding the MIDGE(R) technology.
With such a transaction, MOLOGEN would secure most of the funds needed for the completion of IMPALA. The remaining part would be raised through further capital measures. A substantial and long-term upside of attractive development payments, as well as sales milestones and royalties, remains with MOLOGEN. This agreement would allow the project to be almost entirely funded until the read-out of the pivotal IMPALA study which is expected in 2020.
The transaction is still subject to the agreement of the parties in a definitive transaction documentation.
In addition to finalizing the IMPALA study, the co-development agreement would provide an opportunity to fully realize the potential of lefitolimod in combination with other immuno-oncology drugs and in additional indications outside the colorectal cancer (CRC) maintenance setting. Success in additional indications would bring in additional milestones and royalties representing substantial value for MOLOGEN.MOLOGEN eligible to receive short-term and milestone payments as well as royalties
As consideration for the global assignment of all rights to lefitolimod and the provision of the co-development services, MOLOGEN would receive short-term as well as development and sales milestone payments comprising the following elements:
First of all, to fund the further development of lefitolimod, MOLOGEN would receive a near-term consideration in the aggregated amount of EUR23 million consisting of (1) an initial purchase price of the global rights in the amount of EUR3 million due at the signing of the definitive transaction documents, (2) subsequent quarterly cash payments reflecting MOLOGEN's budgeted expenses for such quarters in a total amount of EUR7 million, and (3) a commitment by ONCOLOGIE to run several clinical trials designed to expand the clinical setting for lefitolimod beyond the IMPALA indication in the amount of EUR9 million. (4) a commitment of ONCOLOGIE to invest a total amount of EUR4 million into two zero interest mandatory convertible bonds ("MCB") with a term of five years and a nominal value of EUR2 million each. Such MCBs would be issued by MOLOGEN to ONCOLOGIE without subscription rights of the existing shareholders backed by the existing conditional capital 2018. The initial conversion price will correspond to the 10-days volume weighted average (stock) price (Xetra) immediately preceding the Company's decision to actually issue the respective MCB plus a 30% premium. The first MCB is envisaged to be issued by 31 August 2018. The second MCB is envisaged to be issued at the time of signing of the final contract.
ONCOLOGIE would place an amount of EUR5 million, including the EUR2 million for the second note and EUR3 million for the global assignment of all intellectual property, in an escrow account within twenty days of signing the term sheet.
The subscription of the first MCB also discharges ONCOLOGIE's equity investment obligation in the amount of EUR2 million under the existing co-development agreement announced on 13 February 2018. The funds referred to under (1), (2) and (4) above (i.e. a total amount of EUR14 million) will be used for the completion of the IMPALA trial until read-out including the preparation of the production upscale. In addition, ONCOLOGIE would invest a minimum of additional EUR9 million in combination studies as part of the co-development agreement beyond IMPALA.
Secondly, ONCOLOGIE would be responsible for all future development activities, including regulatory interactions and production of drug material to support the future commercialization of lefitolimod.
Thirdly, the parties agreed on development and commercialization milestones. They would be due upon reaching predefined development steps as well as market approval. MOLOGEN would be eligible to receive up to approximately EUR200 million in development and regulatory milestone payments based on IMPALA success, and on the success of additional indications that the parties intend to further explore. After registration of lefitolimod in major territories, additional commercial milestones could add up to more than EUR900 million depending on potential future sales. Furthermore, ONCOLOGIE would pay MOLOGEN tiered royalties on a low double-digit percentage average with a peak rate of 16%. In case of a licensing by ONCOLOGIE to a third party outside Greater China, MOLOGEN is entitled to receive 35% of all licensing receipts in condition of a positive read-out of the IMPALA study and otherwise 30% but not less than 50% of the agreed milestones and royalties for territories outside Greater China. In the event Oncology would commercialize lefitolimod on their own or by licensees in the Greater China territory, MOLOGEN would receive 100% of the agreed milestone payments and royalties.
The parties have agreed on a three months exclusivity period to negotiate the definitive transaction documentation. A condition for the closing of the assignment of all rights in lefitolimod is the further funding of ONCOLOGIE in a mid-double-digit million amount.ONCOLOGIE, Inc
ONCOLOGIE is an oncology therapeutics company committed to delivering better outcomes for cancer patients through an improved understanding of which patients will benefit from each drug in the pipeline. The current pipeline is focused on mid-stage clinical programs that modify the immune system to enhance efficacy of current standards of care and emerging immunotherapy agents. Headquartered in Boston, Massachusetts and Shanghai, China, Oncologie is working with global partners to acquire and develop innovative drugs for cancer patients around the world. WWW.ONCOLOGIE.INTERNATIONAL

MOLOGEN AG
MOLOGEN AG is a biopharmaceutical Company and a pioneer in the field of immunotherapy on account of its unique active agents and technologies. Alongside a focus on immuno-oncology, MOLOGEN develops immunotherapies for the treatment of infectious diseases.
The focus of the development work is on the product family of DNA-based TLR9 agonists. This includes the lead compound lefitolimod and the next-generation molecule family EnanDIM(R).

The immunotherapeutic agent lefitolimod is the Company's lead compound and is currently being investigated in a pivotal trial. It is regarded as the best-in-class TLR9 agonist. Treatment with lefitolimod triggers a broad and strong activation of the immune system. On account of this mode of action, lefitolimod could potentially be used in various indications. Lefitolimod is currently being developed within the framework of a pivotal study for first line maintenance therapy for colorectal cancer. Key data of the phase II IMPULSE study in small cell lung cancer have been announced in April 2017, and the final analysis in the first quarter 2018 confirmed the data. Furthermore, data from the extension phase of the TEACH study in HIV have also been published in 2017. In addition, lefitolimod is currently being investigated in a phase I combination study with the checkpoint inhibitor ipilimumab (Yervoy(R)) in various cancer indications.
Along with various checkpoint inhibitors, lefitolimod, which is being investigated as part of a phase III clinical trial currently, is one of the few near-to-market product candidates in the field of immuno-oncology.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat diseases for which there is a great medical demand in particular.

MOLOGEN AG is a publicly listed Company, headquartered in Berlin. The shares (ISIN, DE000A2LQ900/SIN: A2L Q90) are listed in the Prime Standard of the German Stock Exchange.www.MOLOGEN.com

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@MOLOGEN.com

Note about risk for future predictionsCertain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

16.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:
English
Company:
MOLOGEN AG

Fabeckstraße 30

14195 Berlin

Germany
Phone:
030 / 841788-0
Fax:
030 / 841788-50
E-mail:
presse@mologen.com
Internet:
www.mologen.com
ISIN:
DE000A2LQ900
WKN:
A2LQ90
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

End of News
DGAP News Service

714731 16.08.2018

https://markets.businessinsider.com/news/stocks/dgap-news-mologen-and-oncologie-global-assignment-and-co-development-agreement-relating-to-mologen-s-lead-compound-lefitolimod-1027463224

"until we get that 8 minute clip translated none of our DD on it means much"

We speak, read Chinese in this house. What I posted is what's going on. They are trying to pump the otc CIIX stock. Forget the Chinese connection.

"CVSI is providing wholesale CBD to chinesecbdoil.com"

Not happening!

None of the Chinese connecting dots here have anything to do with CVSI other then the fact that CVSI's SP is going up and that's what they are discussing in the Chinese speaking youtube video. The person being interviewed, Warren Wang, is only talking about their own product which is not from CVSI. On top of that, the news group "Chineseefn." that appears to be interviewing Wang is a division of the Chinese CBD oil company and they all share the same addresses. It's quite an amazing scam actually.

“Why do we care about how many shares are authorized if the BOD doesn’t plan on using then”

There is just nothing left to pump anymore!

What a joke saying the "poison pill" is still intact is a positive and this coming from the same group who condemned it all those years. First off, what company in their right mind would want to do a hostile take-over of a company with leased space that's half empty and not producing anything and almost 50% percent short of capacity in the workable space. A work force of 125 with very little to work on and a company paying a 10.5% dividend on a preferred stock. I'm sure some big company is just clamoring to get us.

I'm beginning to wonder if the $10 Janney estimate will be the buyout price offered to shareholders? This would be absouletly fine, just keep buying now.

Sub $5 this week?

Big shout out of thanks to Johnny and Little Stevie for all these trading opportunities!

Only way to make any money here is to trade this sucker to death.

Lias said 18 months but that didn't include FDA inspections so late 2020 would be a safe guess.

Expand for what? They are $50M shy of capacity now.

This isn't Field of Dreams, "build it and they will come". We don't have a half decent contract yet.

IMO

"we had our $5.47 moment yesterday...I say we S-l-o-w-l-y mount
a push back up to $6.00 by EOD....IMHO...GLTA.. "

Mr. Sid, what happened?

Maybe the entity who dropped $1.5 M yesterday wants it to go up?

As you previously stated from a day or so ago....

"Someone somewhere has an order in for a chunk of AVID and the MMs are buying the stock up on retail orders to accumulate enough for the mystery purchaser...The MMs want to accommodate but they will
need some inventory...............GLTA.... "

New here but been around long enough to know when the “Chart Video” guy shows up it’s not a good thing!

FWIW

Being $60M+ short of capacity they are probably not going to do a placement for expansion. How much of those Oncologie dollars were used to pay the 10.5% CDMOP interest payments. Is a placement a possibility to buy back those shares that are eating up income?

Only the insiders know.

IMO

Man Beats Pot Charges With Unusual Strategy: Admit Guilt

Javonnie McCoy puts himself at mercy of jury, and they side with him over the law

John Johnson
(Newser) – It's illegal to grow marijuana in Georgia, meaning things didn't look good for Javonnie McCoy when police busted him with nearly a pound of home-grown pot in his residence. Things surely looked worse for him when he got in front of a jury in Dublin, Georgia, and flat-out admitted that the pot was his and, yes, he did grow it. The jury's decision was seemingly a no-brainer because the law is crystal clear—and yet jurors found him not guilty last week. As Bill Torpy of the Atlanta Journal-Constitution explains, it may have been because of an unusual legal strategy used by McCoy's attorney called jury nullification. Essentially, attorney Catherine Bernard told the panel that a jury has the power to "nullify a law it disagrees with—at least as it pertains to the specific case under consideration," per a post at FitsNews.

In this case, she argued that it made no sense to send an otherwise law-abiding citizen to prison over some pot plants. As Marijuana Moment notes, the judge would have had no choice but to impose a mandatory one-year sentence if a guilty verdict had come back. McCoy had told the court that he was beaten into a coma in 2003 and that marijuana is about the only thing that helps with the lingering pain and trauma. "The jury appreciated his honesty throughout the case ... and recognized that a good, hard working man living a quiet life and not bothering anyone didn't deserve a felony conviction for his actions," writes Bernard in a Facebook post. For the record, she dislikes the term jury nullification. "It's simply part of being a jury," she says. "The jury judges the law and the facts." McCoy tells Torpy it helped that the jury was made up of working-class people like himself. "They saw I wasn't bothering nobody."

http://www.newser.com/story/262563/man-beats-pot-charges-with-unusual-strategy-admit-guilt.html

It's a signal they are going to take it down more on Monday. When they tell you this thing is going up and never going to stop they're selling their shares and vice versa, here comes the yearly lows, they're buying more. Market loves screwing with everybody's head, just more manipulation. Nothing we all don't already know.

IMO

$5.45 good buy back point, seems to be support there.

I guess pre-market signal was just that.

"I saw the bid then realized it was meaningless."

It's always a curious thing when some suggest we are going UP when we are actually going down.

$5.44 on 288 pre-market.........

What say the NEW Pied Pipers to that?

"I wonder how much our new hedge fund "friends" contributed to the rapid late afternoon decline?"

Congrats to all of us who didn't........

wait for $7.....

secret Bavi news.......

or

the sale of the company.......!

Interesting, the short volume was largest, 1,092,574 on 7/17 when we made the big move up to $5.50.

Lets hope beating the shorts continues.

Avid Short Interest UP 2,589,957 from previous.

Settlement Date.....Short Interest.....Avg Daily Share Volume.....Days To Cover

6/29/2018......3,491,648......1,063,710......3.282519
6/15/2018......901,691......309,316......2,915,113

https://www.nasdaq.com/symbol/cdmo/short-interest

Hats off to Johnny & Little Stevie.......!

As I posted, when we got over $5 I would no longer trash them.

When we get to $7 I will even change my profile pic.

My late day yesterday $4.45 purchase of 5K was a great trade at $5.60. I've officially joined the CDMO Flipper Club.

Happy trading........

and like you I've been buying all along.

GLTAL